-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although Usnu monoantigen has been recommended by the guidelines as a second-line biological agent for the treatment of Crohn's disease, there are still some patients who have a loss of response to Usnu monoantigen.
90 milligrams of medication is used every eight weeks during using the single anti-maintenance treatment, this study aims to explore whether shortening the time interval between dosing may benefit the treatment of Crohn's disease.
researchers used retrospective studies to assess the effectiveness of shortening the dose interval between usanu monoantigens, which collected data from 506 patients who received 90 mg of ussin monoantigens every 8 weeks.
110 other patients initially received sub-skin injections of usanut 90 mg every 8 weeks, and then the interval was reduced to every 4 weeks.
Bradshaw index (HBI) score before and after shortening dose intervals in the queue was applied to 78 patients (71%) and 60 patients with C-reactive protein (CRP) levels (55%).
results showed that after the dose interval was shortened, the patient's median HBI was reduced from 4.5 to 3 (P-.002), the median CRP was reduced from 8 mg/L to 3 mg/L (P=.031), and the median fecal calcium-guard protein was reduced from 378?g/g to 157?g/g (P.57).
in patients with HBI,4, CRP levels ≥5mg / dL, fecal calcium protein levels 250ug / g, or endoscopic evidence of disease activity before shortening the dose interval, after shortening the dose interval, 28% of patients received clinical remission (HBI score ≤4), 22% of patients returned to normal levels of CRP (-lt;5 mg/dL), 50% of fecal calcium protein levels decreased, and 36% had endoscopic remission.
the study, researchers confirmed that reducing the interval between usanu monoantigens to four weeks for non-responsive CD patients at 90 mg per 8 weeks could improve clinical and biological indicators of disease activity.
。